<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771537</url>
  </required_header>
  <id_info>
    <org_study_id>0601-09</org_study_id>
    <secondary_id>R01NR010004</secondary_id>
    <nct_id>NCT00771537</nct_id>
  </id_info>
  <brief_title>HIV Testing &amp; Womens Attitudes on HIV Vaccine Trials</brief_title>
  <official_title>HIV Testing &amp; Womens Attitudes on HIV Vaccine Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects of different persuasive informational
      messages on rates of rapid HIV testing and willingness to participate in a HIV vaccine
      clinical trial. Adult African-American, non-Latina White, and Latina women will be recruited.
      Women will initially be randomized to 4 groups: 1. no message control; 2. 1-sided message
      that mentions benefits of HIV testing; 3. 2-sided message that acknowledges minor opposition
      to testing, then refutes the opposition; and 4. 2-sided message that acknowledge stronger
      opposition to testing, then refutes the opposition. Women will be offered HIV testing, then
      re-randomized to a similar set of 4 messages related to HIV vaccine trials. There will
      therefore be 16 groups in total (4 X 4).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 5-year proposal responds to PAS-03-168, &quot;Enrolling Women and Minorities in HIV/AIDS
      Research Trials.&quot; This study seeks to evaluate persuasive message interventions to increase
      HIV testing rates and improve acceptability of participation in a phase 3 HIV vaccine
      clinical trial among African-American, Latina, and White women. We plan to evaluate 1-sided
      messages, which mention only the benefits of an action, versus 2-sided messages, which
      mention negative aspects of the action, followed by positive counterarguments. The Health
      Belief Model, Inoculation and Attribution Theories will guide the research. Participants will
      be women attending urban community health clinics in Indianapolis, IN. Specific Aim 1 is to
      identify obstacles to HIV testing and to participation in a HIV vaccine clinical trial. This
      aim will be accomplished in years 1 and 2 through individual semi-structured interviews. We
      will analyze data via thematic content analysis and will use interview findings to assist in
      the development of measures and interventions employed in the intervention phase (years 3-5).
      Specific Aim 2 is to evaluate the effects of 2-sided versus 1-sided persuasive messages on
      rates of acceptance of rapid HIV testing. Demographic, behavioral, and attitudinal measures
      will be administered via audio computer-assisted self-interview (A-CASI). Participants will
      be randomized to the intervention groups via A-CASI as well. The outcome will be
      acceptance/rejection of free rapid HIV testing. This Aim will be evaluated via binary
      logistic regression. Specific Aim 3 is to evaluate the effects of 2-sided versus 1-sided
      messages on willingness to participate in phase 3 clinical trials for a preventive HIV
      vaccine. Participants will complete this 2nd A-CASI survey and will again be randomized to
      intervention groups. The outcome will be a scale measuring acceptability of clinical trial
      participation. This Aim will be evaluated via one-way Analysis of Variance. This study is
      relevant to public health in that the results may help us to understand how to improve
      enrollment of women and minorities into preventive HIV vaccine clinical trials and how to
      encourage women and minorities to get tested for HIV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Accepted Rapid HIV Testing.</measure>
    <time_frame>During study visit. At approximately 30 minutes into the study visit. After part 1 of the questionnaire was completed.</time_frame>
    <description>Acceptance of rapid HIV testing. Acceptance was assessed by actual administration of rapid oral HIV test by research staff.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Willingness to Participate in a HIV Vaccine Clinical Trial</measure>
    <time_frame>Approximately 60 minutes into the study visit, at the end of Part 2 of the questionnaire.</time_frame>
    <description>Willingness to Participate in a HIV Vaccine Clinical Trial. Assessed via participant self-report with 6 items on Part 2 of the questionnaire. Item responses measured on 5-point Likert-type scale ranging from Strongly Disagree (value = 1) to Strongly Agree (value = 5).</description>
  </primary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">2031</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Arm 1. Control PLUS Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2. Control PLUS 1-Sided</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3. Control PLUS 2-Sided Trivial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4. Control PLUS 2-Sided Major</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5. 1-Sided PLUS Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6. 1-Sided PLUS 1-Sided</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7. 1-Sided PLUS 2-Sided Trivial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 8. 1-Sided PLUS 2-Sided Major</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9. 2-Sided Trivial PLUS Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 10. 2-Sided Trivial PLUS 1-Sided</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 12. 2-Sided Trivial PLUS 2-Sided Major</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 13. 2-Sided Major PLUS Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 14. 2-Sided Major PLUS 1-Sided</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 15. 2-Sided Major PLUS 2-Sided Trivial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 16. 2-Sided Major PLUS 2-Sided Major</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Message Sidedness</intervention_name>
    <description>There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.</description>
    <arm_group_label>Arm 2. Control PLUS 1-Sided</arm_group_label>
    <arm_group_label>Arm 3. Control PLUS 2-Sided Trivial</arm_group_label>
    <arm_group_label>Arm 4. Control PLUS 2-Sided Major</arm_group_label>
    <arm_group_label>Arm 5. 1-Sided PLUS Control</arm_group_label>
    <arm_group_label>Arm 6. 1-Sided PLUS 1-Sided</arm_group_label>
    <arm_group_label>Arm 7. 1-Sided PLUS 2-Sided Trivial</arm_group_label>
    <arm_group_label>Aim 8. 1-Sided PLUS 2-Sided Major</arm_group_label>
    <arm_group_label>Arm 9. 2-Sided Trivial PLUS Control</arm_group_label>
    <arm_group_label>Arm 10. 2-Sided Trivial PLUS 1-Sided</arm_group_label>
    <arm_group_label>Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial</arm_group_label>
    <arm_group_label>Arm 12. 2-Sided Trivial PLUS 2-Sided Major</arm_group_label>
    <arm_group_label>Arm 13. 2-Sided Major PLUS Control</arm_group_label>
    <arm_group_label>Arm 14. 2-Sided Major PLUS 1-Sided</arm_group_label>
    <arm_group_label>Arm 15. 2-Sided Major PLUS 2-Sided Trivial</arm_group_label>
    <arm_group_label>Arm 16. 2-Sided Major PLUS 2-Sided Major</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18 years of age or older

          -  Able to understand English or Spanish

          -  Able to give informed consent

        Exclusion Criteria:

          -  Not female

          -  Under 18 years of age

          -  Not able to understand English and Spanish

          -  Unable to give informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory D Zimet, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Medical Group Clinics</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Burrage JW, Zimet GD, Cox DS, Cox AD, Mays RM, Fife RS, Fife KH. The Centers for Disease Control and Prevention revised recommendations for HIV testing: reactions of women attending community health clinics. J Assoc Nurses AIDS Care. 2008 Jan-Feb;19(1):66-74. doi: 10.1016/j.jana.2007.11.003.</citation>
    <PMID>18191770</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <results_first_submitted>April 7, 2013</results_first_submitted>
  <results_first_submitted_qc>June 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2013</results_first_posted>
  <last_update_submitted>June 28, 2013</last_update_submitted>
  <last_update_submitted_qc>June 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Gregory Zimet</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV Testing</keyword>
  <keyword>Persuasion</keyword>
  <keyword>Health Communication</keyword>
  <keyword>Clinical Trials Participation</keyword>
  <keyword>Attitudes toward Health</keyword>
  <keyword>Diagnostic Tests</keyword>
  <keyword>Behavioral Research</keyword>
  <keyword>Intervention Studies</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Message intervention details are in the Brief Summary</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG Control</title>
          <description>No message intervention control condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P2">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 1-Sided</title>
          <description>No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P3">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>No message intervention control condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P4">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>No message intervention control condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P5">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG Control</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P6">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 1-Sided</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P7">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P8">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P9">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG Control</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P10">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 1-Sided</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P11">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Trivia</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P12">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P13">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG Control</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P14">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 1-Sided</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P15">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="P16">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="114"/>
                <participants group_id="P5" count="127"/>
                <participants group_id="P6" count="118"/>
                <participants group_id="P7" count="128"/>
                <participants group_id="P8" count="132"/>
                <participants group_id="P9" count="115"/>
                <participants group_id="P10" count="119"/>
                <participants group_id="P11" count="133"/>
                <participants group_id="P12" count="137"/>
                <participants group_id="P13" count="128"/>
                <participants group_id="P14" count="124"/>
                <participants group_id="P15" count="124"/>
                <participants group_id="P16" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="124"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="114"/>
                <participants group_id="P5" count="127"/>
                <participants group_id="P6" count="118"/>
                <participants group_id="P7" count="128"/>
                <participants group_id="P8" count="132"/>
                <participants group_id="P9" count="115"/>
                <participants group_id="P10" count="119"/>
                <participants group_id="P11" count="133"/>
                <participants group_id="P12" count="137"/>
                <participants group_id="P13" count="128"/>
                <participants group_id="P14" count="124"/>
                <participants group_id="P15" count="124"/>
                <participants group_id="P16" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG Control</title>
          <description>No message intervention control condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B2">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 1-Sided</title>
          <description>No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B3">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B4">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B5">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG Control</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B6">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 1-Sided</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B7">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B8">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B9">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG Control</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B10">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 1-Sided</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B11">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Trivia</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B12">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B13">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG Control</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B14">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 1-Sided</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B15">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B16">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="B17">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
            <count group_id="B2" value="124"/>
            <count group_id="B3" value="151"/>
            <count group_id="B4" value="114"/>
            <count group_id="B5" value="127"/>
            <count group_id="B6" value="118"/>
            <count group_id="B7" value="128"/>
            <count group_id="B8" value="132"/>
            <count group_id="B9" value="115"/>
            <count group_id="B10" value="119"/>
            <count group_id="B11" value="133"/>
            <count group_id="B12" value="137"/>
            <count group_id="B13" value="128"/>
            <count group_id="B14" value="124"/>
            <count group_id="B15" value="124"/>
            <count group_id="B16" value="122"/>
            <count group_id="B17" value="2031"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="104"/>
                    <measurement group_id="B5" value="119"/>
                    <measurement group_id="B6" value="111"/>
                    <measurement group_id="B7" value="121"/>
                    <measurement group_id="B8" value="124"/>
                    <measurement group_id="B9" value="111"/>
                    <measurement group_id="B10" value="112"/>
                    <measurement group_id="B11" value="126"/>
                    <measurement group_id="B12" value="128"/>
                    <measurement group_id="B13" value="118"/>
                    <measurement group_id="B14" value="120"/>
                    <measurement group_id="B15" value="118"/>
                    <measurement group_id="B16" value="119"/>
                    <measurement group_id="B17" value="1909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="10"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="14"/>
                    <measurement group_id="B2" value="44" spread="14"/>
                    <measurement group_id="B3" value="47" spread="13"/>
                    <measurement group_id="B4" value="45" spread="15"/>
                    <measurement group_id="B5" value="44" spread="13"/>
                    <measurement group_id="B6" value="44" spread="12"/>
                    <measurement group_id="B7" value="44" spread="14"/>
                    <measurement group_id="B8" value="45" spread="14"/>
                    <measurement group_id="B9" value="42" spread="13"/>
                    <measurement group_id="B10" value="44" spread="13"/>
                    <measurement group_id="B11" value="44" spread="13"/>
                    <measurement group_id="B12" value="43" spread="13"/>
                    <measurement group_id="B13" value="46" spread="13"/>
                    <measurement group_id="B14" value="44" spread="13"/>
                    <measurement group_id="B15" value="44" spread="12"/>
                    <measurement group_id="B16" value="42" spread="13"/>
                    <measurement group_id="B17" value="44" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="127"/>
                    <measurement group_id="B6" value="118"/>
                    <measurement group_id="B7" value="128"/>
                    <measurement group_id="B8" value="132"/>
                    <measurement group_id="B9" value="115"/>
                    <measurement group_id="B10" value="119"/>
                    <measurement group_id="B11" value="133"/>
                    <measurement group_id="B12" value="137"/>
                    <measurement group_id="B13" value="128"/>
                    <measurement group_id="B14" value="124"/>
                    <measurement group_id="B15" value="124"/>
                    <measurement group_id="B16" value="122"/>
                    <measurement group_id="B17" value="2031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="127"/>
                    <measurement group_id="B6" value="118"/>
                    <measurement group_id="B7" value="128"/>
                    <measurement group_id="B8" value="132"/>
                    <measurement group_id="B9" value="115"/>
                    <measurement group_id="B10" value="119"/>
                    <measurement group_id="B11" value="133"/>
                    <measurement group_id="B12" value="137"/>
                    <measurement group_id="B13" value="128"/>
                    <measurement group_id="B14" value="124"/>
                    <measurement group_id="B15" value="124"/>
                    <measurement group_id="B16" value="122"/>
                    <measurement group_id="B17" value="2031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Accepted Rapid HIV Testing.</title>
        <description>Acceptance of rapid HIV testing. Acceptance was assessed by actual administration of rapid oral HIV test by research staff.</description>
        <time_frame>During study visit. At approximately 30 minutes into the study visit. After part 1 of the questionnaire was completed.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No message intervention control condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
          </group>
          <group group_id="O2">
            <title>1-Sided</title>
            <description>1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
          </group>
          <group group_id="O3">
            <title>2-Sided Trivial</title>
            <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
          </group>
          <group group_id="O4">
            <title>2-Sided Major</title>
            <description>2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Accepted Rapid HIV Testing.</title>
          <description>Acceptance of rapid HIV testing. Acceptance was assessed by actual administration of rapid oral HIV test by research staff.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="505"/>
                <count group_id="O3" value="504"/>
                <count group_id="O4" value="498"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458"/>
                    <measurement group_id="O2" value="401"/>
                    <measurement group_id="O3" value="410"/>
                    <measurement group_id="O4" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.50</ci_lower_limit>
            <ci_upper_limit>.96</ci_upper_limit>
            <estimate_desc>Women in the 1-sided message group accepted testing at a lower rate (79.4%) than those in the control group (87.4%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.10</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.54</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Women in the 2-sided trivial group were no different in their acceptance rate of HIV testing (81.3%) than women in the control group (87.4%).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.63</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.176</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.65</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>Women in the 2-sided major group were no different in rates of accepting HIV testing (83.9%) than women in the control group (87.4%)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Willingness to Participate in a HIV Vaccine Clinical Trial</title>
        <description>Willingness to Participate in a HIV Vaccine Clinical Trial. Assessed via participant self-report with 6 items on Part 2 of the questionnaire. Item responses measured on 5-point Likert-type scale ranging from Strongly Disagree (value = 1) to Strongly Agree (value = 5).</description>
        <time_frame>Approximately 60 minutes into the study visit, at the end of Part 2 of the questionnaire.</time_frame>
        <population>Only participants who answered the Willingness to Participate questions on the survey were included in these analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Control/Control</title>
            <description>No message intervention control condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
          </group>
          <group group_id="O2">
            <title>1-Sided</title>
            <description>No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
          </group>
          <group group_id="O3">
            <title>2-Sided Trivial</title>
            <description>No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.</description>
          </group>
          <group group_id="O4">
            <title>2-Sided Major</title>
            <description>No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.</description>
          </group>
        </group_list>
        <measure>
          <title>Willingness to Participate in a HIV Vaccine Clinical Trial</title>
          <description>Willingness to Participate in a HIV Vaccine Clinical Trial. Assessed via participant self-report with 6 items on Part 2 of the questionnaire. Item responses measured on 5-point Likert-type scale ranging from Strongly Disagree (value = 1) to Strongly Agree (value = 5).</description>
          <population>Only participants who answered the Willingness to Participate questions on the survey were included in these analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="530"/>
                <count group_id="O4" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="1.15"/>
                    <measurement group_id="O2" value="2.52" spread="1.18"/>
                    <measurement group_id="O3" value="2.55" spread="1.18"/>
                    <measurement group_id="O4" value="2.47" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-way Analysis of Variance</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.60</p_value>
            <method>ANOVA</method>
            <method_desc>Degrees of freedom = (1,978)</method_desc>
            <param_type>Marginal Means</param_type>
            <param_value>2.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.42</ci_lower_limit>
            <ci_upper_limit>2.56</ci_upper_limit>
            <estimate_desc>There was no significant effect for the 1-sided message compared to the control group on Willingness to Participate in an HIV vaccine clinical trial.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-Way Analysis of Variance</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.25</p_value>
            <method>ANOVA</method>
            <method_desc>degrees of freedom = (1,1028)</method_desc>
            <param_type>Marginal Means</param_type>
            <param_value>2.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.44</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
            <estimate_desc>There was no significant effect for the 2-sided trivial message compared to the control group on Willingness to Participate in an HIV vaccine clinical trial.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-Way Analysis of Variance</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.91</p_value>
            <method>ANOVA</method>
            <param_type>Marginal Means</param_type>
            <param_value>2.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.40</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
            <estimate_desc>There was no significant effect for the 2-sided major message compared to the control group on Willingness to Participate in an HIV vaccine clinical trial.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG Control</title>
          <description>No message intervention control condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E2">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 1-Sided</title>
          <description>No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E3">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E4">
          <title>HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E5">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG Control</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E6">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 1-Sided</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E7">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E8">
          <title>HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E9">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG Control</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E10">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 1-Sided</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E11">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Trivia</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E12">
          <title>HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E13">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG Control</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E14">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 1-Sided</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E15">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Trivial</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
        <group group_id="E16">
          <title>HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Major</title>
          <description>2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gregory D Zimet</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-274-8812</phone>
      <email>gzimet@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

